Evidence map›Paper›PMID 17891553›Full record

ArticlePharmaceutical research2008

Formulation and characterization of injectable poly(DL-lactide-co-glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor.

Kashappa Goud H Desai, Susan R Mallery, Steven P Schwendeman

Abstract read
In one paragraph

Article in Pharmaceutical research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 38 citations in OpenAlex.

  1. Local controlled release of stabilized monoclonal antibodies.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article
  2. Article
  3. RepositioningPharmaceutics · 2020
    Article
  4. IET nanobiotechnology · 2020
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DL-lactide-co-glycolide) implants.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2008
    Article
  13. Effects of a topically applied bioadhesive berry gel on loss of heterozygosity indices in premalignant oral lesions.Clinical cancer research : an official journal of the American Association for Cancer Research · 2008
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Kashappa Goud H DesaiDepartment of Pharmaceutical Sciences, University of Michigan, 428 Church St., Ann Arbor, Michigan 48109-1065, USA.
Susan R Mallery
Steven P Schwendeman
University of Michigan–Ann Arbor · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · US

Funding

Protein Stability in Polymer Delivery SystemsR01HL068345 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHWENDEMAN, STEVEN P. · 2001 to 2011
$2.8M
Chemoprevention of Head & Neck Cancer Using Controlled Release PolymersR01CA129609 · NCI · OHIO STATE UNIVERSITY · PI MALLERY, SUSAN R · 2009 to 2013
$1.5M
Role of Oxidants &Angiogenesis in Kaposi's SarcomaR01CA095901 · NCI · OHIO STATE UNIVERSITY · PI MALLERY, SUSAN R · 2003 to 2007
$1.4M
NCI NIH HHS R01 CA095901NCI NIH HHS R01 CA129609NCI NIH HHS R01 CA95901NHLBI NIH HHS R01 HL068345NHLBI NIH HHS R01 HL68345
6 · The paper itself

Abstract

purposeThe objective of this study was to develop poly(lactic-co-glycolic acid) (PLGA) injectable implants (i.e., millicylinders) with microencapsulated N-acetylcysteine (NAC) for site-specific controlled NAC release, for potential chemopreventive applications in persons with previously excised head and neck cancers.

methodsPLGA 50:50 (i.v.=0.57 dl/g) implants with 1-10 wt% NAC free acid or 10 wt% NAC salts (NAC-Na+, NAC-Mg2+ and NAC-Ca2+) were prepared by solvent extrusion and/or fluid energy micronization (FEM) methods. X-ray diffraction (XRD), scanning electron microscopy (SEM), and differential scanning calorimetry (DSC) studies were performed to evaluate the physical mixing of NAC with PLGA. PLGA implant degradation was studied by kinetics of polymer molecular weight decline (gel permeation chromatography) and mass loss. Release studies were conducted in N2 purged PBS (pH 7.4) at 37 degrees C in evacuated and sealed ampoules. NAC was quantified by HPLC at 210 nm.

resultsXRD, SEM and DSC studies indicated that NAC had dissolved in the polymer phase at 1-3.5% w/w loading, but became discretely suspended in the polymer at 6-10% w/w. Initial burst and long-term release rate increased with increased drug loading, and release was uncharacteristically rapid at higher loading (6-10% w/w). The cause of the rapid release was linked to extensive plasticization, matrix porosity and general acid catalysis of PLGA degradation caused by the NAC free acid. PLGA millicylinders loaded with 10% w/w NAC-Ca2+ and NAC-Mg2+salts exhibited reduced burst (34 vs 13-22% release within a day of incubation for NAC free acid vs NAC-Ca2+ and NAC-Mg2+salts, respectively) and slow and continuous complete release over 4 weeks without significant NAC-catalyzed degradation of PLGA. Release of NAC from NAC-Ca2+/PLGA implant was slower than that of NAC-Mg2+/PLGA consistent with the lower solubility of the former salt. NAC with its free thiol was rapidly converted to its cystine dimer in the presence of molecular oxygen. PLGA released samples in sealed and evacuated ampoules indicated>80% parent NAC remaining after the 1 month release analysis irrespective of initial NAC free acid and salt forms.

conclusionBy encapsulating the NAC-Mg2+ and NAC-Ca2+ salts in PLGA implants, the high initial burst, short release duration, and the general acid catalysis caused by the NAC free acid were each prevented and 1-month slow and continuous release was attained with minimal instability of the free thiol group.

Indexed as

Drug CarriersMatrix Metalloproteinase InhibitorsAcetylcysteineAnimalsAntineoplastic AgentsCalcium CompoundsCalorimetry, Differential ScanningCatalysisChemistry, PharmaceuticalDrug CompoundingDrug ImplantsDrug StabilityHead and Neck NeoplasmsHumansInjectionsKineticsAcetylcysteineAntineoplastic AgentsCalcium CompoundsDrug CarriersDrug ImplantsLactic AcidMagnesium CompoundsMatrix Metalloproteinase InhibitorsPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerPolymersProtease Inhibitors

Identifiers

PMID17891553
PMCPMC2405913
OpenAlexW2095362233

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.